SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike stock is trending as investors react to a significant sell-off following disappointing revenue guidance and projections of a steep decline in the Chinese market. Community sentiment is deeply divided, with some investors viewing the price drop as a rare entry point for a long-term 'dividend aristocrat' play, while others warn of a 'value trap' due to stalled growth and ongoing concerns regarding management's turnaround strategy.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is attracting heavy investor attention as the company moves its earnings report to April 1st, fueling speculation about a potential surprise and the upcoming impact of U.S. federal cannabis rescheduling. While bulls are pointing to recent beverage partnerships and potential growth in the CBD pilot program as key catalysts for a rally, bearish participants remain focused on concerns regarding share dilution and the company's management track record.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar is experiencing intense speculative momentum as investors closely monitor reports of a potential acquisition, with SpaceX and Amazon frequently cited as the primary parties vying for the company's critical satellite spectrum. The community is actively debating the timing of an official announcement, particularly as Globalstar approaches a scheduled earnings call and industry observers look for signs of a strategic move to secure the company's direct-to-device infrastructure.

RH operates as a holding company which operates the business through its subsidiary Restoration Hardware, Inc. It offers furniture, lighting, textiles, bath ware, decor, outdoor and garden, as well as baby and child products. The company operates an integrated business with multiple channels of distribution including galleries, source books and websites. The company was founded by Stephen J. Gordon in 1980 and is headquartered in Corte Madera, CA.

RH - Ordinary Shares - Class A

Restoration Hardware

Restoration Hardware is seeing intense market volatility and debate following a mixed earnings report that missed profit estimates, with investors weighing the company's long-term global expansion plans against ongoing headwinds from the challenging housing market and complex tariff impacts. The community remains deeply divided, with some traders hunting for a short-term squeeze or long-term value entry, while others express skepticism over the company's high debt levels and luxury furniture demand in the current economic climate.

Mega Fortune Co., Ltd. operates as a holding company which provides information technology services. It specializes in delivering comprehensive IoT solutions and services across various industries. The firm offers low carbon property management, energy, stock and GreenTech management services. The company was founded in 2011 and is headquartered in Hong Kong.

Mega Fortune Co Ltd.

Mega Fortune Company Limited

Mega Fortune Company Limited is generating significant trading volume as traders speculate on its potential for volatile price swings common among low-float Chinese IPOs. The community is actively debating whether the stock will mirror historical patterns of massive short-term surges or succumb to typical pump-and-dump mechanics, with many monitoring its low float and share lock-up status.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience is seeing heightened activity driven by its reputation as a volatile, low-float runner, with investors intensely debating whether it will repeat past parabolic short squeezes. Community discussions are heavily split between those betting on another massive upside move fueled by tight share availability and those warning of the risks inherent in the stock's speculative, pump-and-dump nature.

SharonAI Holdings, Inc. engages in providing high-performance computing (HPC), artificial intelligence (AI), and cloud GPU compute infrastructure technologies. The company was founded on December 30, 2024 and is headquartered in New York, NY.

SharonAI Holdings Inc. - Ordinary Shares - Class A

SharonAI is trending due to the announcement of a massive multi-year AI infrastructure contract, which has sparked intense community debate regarding its low-float potential for a significant squeeze. Investors are actively discussing the stock's future, weighing the deal's long-term value against frustrations over current volume, price action, and perceived manipulation.

Hertz Global Holdings, Inc. engages in the vehicle rental business through the Hertz, Dollar, and Thrifty brands. It operates under the Americas Rental Car (RAC) and International Rental Car (RAC) segments. The Americas RAC segment focuses on operations in the United States, Canada, Latin America, and the Caribbean. The International RAC segment includes the provision of rental and sales of vehicles and value-added services in other locations. The company was founded in 1918 and is headquartered in Estero, FL.

Hertz Global Holdings Inc. - Ordinary Shares (New)

Hertz Global Holdings Inc

Hertz is seeing heightened community discussion and bullish sentiment following a significant stake acquisition by Bill Ackman, driving speculation about a potential turnaround and a massive short squeeze. Investors are closely monitoring key technical resistance levels while debating the impact of upcoming debt obligations and the company's long-term strategy.

Tema ETF Trust - Tema Space Innovators ETF

The Tema Space Innovators ETF is trending as investors seek exposure to the anticipated SpaceX IPO and broader space sector growth. While some community members are optimistic about its focus on space technology and satellite infrastructure, others are actively debating its low assets under management and comparing its potential performance and strategy to other existing space-linked investment vehicles.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet Inc. (GOOGL) is seeing heightened volatility as investors weigh the potential long-term benefits of the company's new 'TurboQuant' AI efficiency software against a broader tech sector sell-off and legal liabilities related to user safety. The community remains deeply divided, with some traders viewing recent pullbacks as a generational buying opportunity, while others are cautious of mounting antitrust litigation and the cooling sentiment surrounding heavy AI infrastructure spending.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Capricor Therapeutics (NASDAQ:CAPR) Stock Passes Above 50 Day Moving Average - What's Next?

Capricor Therapeutics (NASDAQ:CAPR) Share Price Passes Above Fifty Day Moving Average - What's Next...

Q1 Earnings Forecast for CAPR Issued By HC Wainwright

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) - Equities researchers at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Capricor Therapeutics in a...

<ul class="summary-bullets"><li>Roth Capital analyst Boobalan Pachaiyappan recommended buying shares of Capricor Therapeutics on Friday's selloff.</li><li>B. Riley, meanwhile, raised the firm's price target on CAPR to $63 from $50 and kept a ‘Buy’ rating on the shares.</li><li>The Food and Drug Administration has lifted the previously issued Complete Response Letter and resumed the review of the Biologics License Application for Deramiocel with a decision expected by August 22.</li></ul>Shares of Capricor Therapeutics (CAPR) fell 9% on Friday after the company reported a wider-than-expected Q4 loss but Wall Street analysts raised their price targets on the stock over hopes for an approval of the company’s lead candidate.On the company’s fourth-quarter (Q4) <a href="https://stocktwits.com/news-articles/markets/equity/capricor-reports-wider-quaterly-loss-than-expected-but-all-eyes-are-on-deramiocel/cZduNXsRIad">earnings</a> call, CEO Linda Marban <a href="https://stocktwits.com/news-articles/markets/equity/capr-stock-best-week-month-ceo-rules-out-conditional-deramiocel-approval/cZdDdk4RIa1">rejected</a> the possibility that the Deramiocel therapy could receive only a conditional regulatory decision. The U.S. Food and Drug Administration is now expected to rule on Capricor's application for Deramiocel in the treatment of Duchenne Muscular Dystrophy by August 22, 2026, after reversing course on its previous rejection. DMD is a genetic disorder characterized by muscle degeneration.<h2 class="st-heading-2">Wall Street Take Aways</h2>Roth Capital analyst Boobalan Pachaiyappan recommended buying shares of Capricor Therapeutics on today's selloff. The 8% pullback is a "transient, healthy and short-lived market correction" following the rally post FDA acceptance of Capricor's application of Deramiocel for the treatment of Duchenne muscular dystrophy, the analyst told investors in a research note. Roth would be buying today's "dislocation" and expects the share price to move towards its price target of $41. The firm has a ‘Buy’ rating on Capricor.B. Riley, meanwhile, raised the firm's price target on CAPR to $63 from $50 and kept a ‘Buy’ rating on the shares. The analyst said that its confidence has increased in a potential smooth approval path for Deramiocel ahead of the August 22 decision date, with shares expected to build into the decision as investors digest additional dataset, the analyst told investors in a research note.Piper Sandler raised the firm's price target on CAPR to $58 from $45 and kept an ‘Overweight’ rating on the shares. The firm noted Capricor ended 2025 with cash of $318 million to fund operations through 2027. The FDA has lifted the previously issued Complete Response Letter and resumed the review of the Biologics License Application for Deramiocel with a decision expected by August 22. Optimistically, the label could include the broad Duchenne muscular dystrophy population, not just DMD cardiomyopathy, Piper argues.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around CAPR stock remained within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> has gained 138% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-will-delay-release-of-cybercab-until-late-2026-owing-to-safety-issues-fund-manager-predicts/cZdDVgaRIO9">Tesla Will Delay The Release Of Cybercab Until Late-2026 Owing To Safety Issues, Fund Manager Predicts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the lCapricor Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CAPR Stock Slumps But Wall Street Reiterates Optimism For Deramiocel Approval

On the company’s fourth-quarter (Q4) earnings call on Thursday, CEO Linda Marban rejected the possibility that the Deramiocel therapy could receive only a conditional approval.

Equity

B. Riley Financial Issues Positive Forecast for Capricor Therapeutics (NASDAQ:CAPR) Stock Price

B. Riley Financial raised their price target on shares of Capricor Therapeutics from $50.00 to $63.00 and gave the stock a "buy" rating in a report on Friday...

Capricor Therapeutics Stock Slides As Q4 Earnings Miss Estimates

Capricor Therapeutics shares are trading lower Friday afternoon after the biotech company reported a wider-than-expected fourth-quarter loss.read more...

Capricor Therapeutics (NASDAQ:CAPR) Shares Down 6.3% - Time to Sell?

Capricor Therapeutics (NASDAQ:CAPR) Trading Down 6.3% - Should You Sell...

Capricor Therapeutics (NASDAQ:CAPR) Given Overweight Rating at Piper Sandler

Piper Sandler reaffirmed an "overweight" rating and issued a $58.00 target price (up from $45.00) on shares of Capricor Therapeutics in a research report on Friday...

Pier Capital LLC Boosts Stock Position in Capricor Therapeutics, Inc. $CAPR

Pier Capital LLC increased its holdings in Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) by 35.0% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund...

<ul class="summary-bullets"><li>CEO Linda Marban dismissed concerns that Deramiocel would receive a conditional approval, citing a trial that met both primary and key secondary endpoints.</li><li>The company is preparing for a potential launch, with its San Diego manufacturing capable of initially treating about 250 patients per year.</li><li>Capricor reported a wider-than-expected Q4 loss of $0.62 per share and no revenue, but ended 2025 with about $318.1 million in cash.</li></ul>Capricor Therapeutics, Inc. (CAPR) CEO Linda Marban has pushed back on regulatory doubts around its Duchenne Muscular Dystrophy (DMD) therapy Deramiocel, saying there is “no way” the drug ends up with only a conditional FDA approval, providing some<a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> is heading for its best week since Feb. 20.<h2 class="st-heading-2">CEO Rejects Conditional Approval Risk For Deramiocel</h2>On the company’s fourth-quarter (Q4) earnings call, CEO Linda Marban rejected the possibility that the therapy could receive only a conditional regulatory decision. “No. There’s no way this would be a conditional approval,” Marban said, noting that the trial supporting the application was a randomized, double-blind, placebo-controlled study that met its primary endpoint as well as key secondary endpoints.The comments came after the U.S. Food and Drug Administration (FDA) accepted Capricor’s&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/capricor-stock-dmd-therapy-phase3-heart-function-results/cZdu4NvRI9m">resubmitted</a> biologics license application for Deramiocel, setting a PDUFA decision date of Aug. 22.&nbsp;Capricor is seeking full approval of Deramiocel for Duchenne muscular dystrophy (DMD) and expects the data to support labeling that reflects benefits in both skeletal muscle and heart disease associated with the condition.<h2 class="st-heading-2">Launch Preparations Underway</h2>The company is also preparing for commercialization if the therapy wins regulatory clearance. Capricor’s San Diego GMP manufacturing facility has already completed its FDA pre-license inspection and is positioned to support an initial commercial launch. The site currently has&nbsp;the capacity to treat about 250 patients per year.Marban said the company plans to begin stockpiling commercial doses once labeling discussions with the FDA are finalized, signaling confidence in the potential approval.Capricor is also expanding manufacturing capacity with additional clean rooms at the same facility, which the company expects could increase production to roughly 2,500 patients per year once fully operational.<h2 class="st-heading-2">Clinical Data Supporting Approval</h2>Deramiocel’s application is supported by results from the Phase 3 Hope-3 trial, which met its primary endpoint measuring upper-limb function and key cardiac endpoints in patients with Duchenne muscular dystrophy. Additional data presented&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/capricor-stock-dmd-therapy-phase3-heart-function-results/cZdu4NvRI9m">this week</a> showed reduced cardiac fibrosis and improvements in functional measures tied to daily activities.Marban said physician sentiment around the therapy has strengthened following the new data. “Physicians who before were hopeful are now convinced,” she said, adding that the company is receiving increasing inquiries about prescribing and availability.<h2 class="st-heading-2">CAPR Q4 Review</h2>Capricor reported a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/capricor-stock-dmd-therapy-phase3-heart-function-results/cZdu4NvRI9m">Q4 loss</a> of $0.62 per share, wider than analysts’ estimate of a $0.55 loss per share. The company reported nil revenue, compared with about $11.1 million a year ago, as milestone payments tied to its partnership with Nippon Shinyaku had already been fully recognized.The company ended 2025 with about $318.1 million in cash, which will fund operations into late 2027.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for CAPR was ‘extremely bullish’ amid over a 700% surge in message volumes over the past month.<figure class="image"><img src="https://news.stocktwits-cdn.com/capr_ss_png_4b733f342d.webp" alt="capr ss.png" width="971" height="145"><figcaption>CAPR sentiment and message volume as of March 13 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/RaymondBabbitt/message/647418188">said</a>, “Congratulations to the Bulls, and to the patients who have been waiting for a miraculous discovery to treat their illness of DMD - Deramiocel, is just around the corner.”<stembedurl>https://stocktwits.com/RaymondBabbitt/message/647418188</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Bentradez/message/647424625">said</a> interest in Deramiocel was strong, noting that participants are expected to join quickly and that others have been reaching out to try to take part, adding that “the demand is there for sure.”<stembedurl>https://stocktwits.com/Bentradez/message/647424625</stembedurl>The stock has surged over 150% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

CAPR Stock Heads For Best Week In Nearly A Month: CEO Says 'No Way' Deramiocel Gets Only Conditional Approval

The FDA has accepted Capricor’s resubmitted biologics license application, setting an Aug. 22 PDUFA decision date for Deramiocel in DMD. 

<ul><li>The company reported no revenue for the period, and ended 2025 with cash, cash equivalents, and marketable securities of about $318.1 million.</li><li>Capricor is now awaiting the U.S. Food and Drug Administration’s decision on the application for Deramiocel by August 22.</li><li>The FDA reversed course on its previous rejection for Deramiocel earlier this week.</li></ul>&nbsp;Shares of Capricor Therapeutics (CAPR) slid down about 2% after-hours on Thursday, after the company reported wider-than-expected quarterly loss, partially offset by optimism for the company’s pipeline.For the fourth quarter, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.capricor.com/investors/news-events/press-releases/detail/340/capricor-therapeutics-reports-fourth-quarter-and-full-year">reported</a> a net loss of $0.62 per share, compared to loss of $0.16 per share in the corresponding quarter of 2024, and more than a Wall Street estimate of a loss of $0.54.The company reported no revenue for the period, and ended 2025 with cash, cash equivalents, and marketable securities of about $318.1 million. The company now believes this to be sufficient to cover anticipated expenses and capital requirements though 2027.<h2 class="st-heading-2">Optimism For Deramiocel Application</h2>The company is now awaiting the U.S. Food and Drug Administration’s decision on the application for Deramiocel by August 22. If approved, the company said that its San Diego GMP manufacturing facility will support a potential commercial launch.“Capricor enters 2026 with important regulatory and clinical momentum as we work toward potential approval of Deramiocel for the treatment of Duchenne muscular dystrophy (DMD),” said Linda Marbán, CEO of Capricor.The FDA is now expected to rule on Capricor's application for Deramiocel in the treatment of Duchenne Muscular Dystrophy by August 22, 2026, after reversing course on its previous rejection. DMD is a genetic disorder characterized by muscle degeneration.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around CAPR stock stayed within ‘extremely bullish’ territory over the past 24 hours while message volume remained at ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> has gained about 156% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/fly-stock-rallies-on-wall-street-spiking-optimism-after-succesful-alpha-launch/cZdujXtRIaP">FLY Stock Rallies On Wall Street’s Spiking Optimism After Successful Alpha Launch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Capricor Reports Wider Quarterly Loss Than Expected But All Eyes Are On Muscle Disease Therapy

For the fourth quarter, the company reported a net loss of $0.62 per share, compared to loss of $0.16 per share in the corresponding quarter of 2024.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Thematic ETFs

Prediction Markets

OpenClaw & Agentic-Directed Trading

Tokenization

Recognizing the tool or mechanism that redefined how we trade. From prediction markets to next-gen tech, this award honors the innovation that pushed the boundaries of access and efficiency in modern finance.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.52	--	--	N/A
Q4 '25	-$0.51	-$0.62	-21.81%	MISSED
Q3 '25	-$0.55	-$0.54	1.22%	BEAT
Q2 '25	-$0.48	-$0.57	-19.75%	MISSED
Q1 '25	-$0.32	-$0.53	-67.37%	MISSED

CAPR
Capricor Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest CAPR News

CAPRCapricor Therapeutics Inc